CN109965290B - Meal replacement powder for improving intestinal flora and application thereof - Google Patents

Meal replacement powder for improving intestinal flora and application thereof Download PDF

Info

Publication number
CN109965290B
CN109965290B CN201711447314.6A CN201711447314A CN109965290B CN 109965290 B CN109965290 B CN 109965290B CN 201711447314 A CN201711447314 A CN 201711447314A CN 109965290 B CN109965290 B CN 109965290B
Authority
CN
China
Prior art keywords
powder
parts
composition
inulin
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711447314.6A
Other languages
Chinese (zh)
Other versions
CN109965290A (en
Inventor
李晓平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Original Assignee
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BGI Shenzhen Co Ltd filed Critical BGI Shenzhen Co Ltd
Priority to CN201711447314.6A priority Critical patent/CN109965290B/en
Publication of CN109965290A publication Critical patent/CN109965290A/en
Application granted granted Critical
Publication of CN109965290B publication Critical patent/CN109965290B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses meal replacement powder for improving intestinal flora and application thereof. The dietary composition provided by the invention comprises at least one selected from the group consisting of kudzuvine root powder, coix seed powder, lily powder, inulin and balsam pear powder. The product can achieve the effect of reducing blood sugar by adjusting intestinal microorganisms of the people with T2D diabetes mellitus, and the raw materials are common food materials without toxic or side effects, so that daily needs of people are met, and the purpose of health can be achieved.

Description

Meal replacement powder for improving intestinal flora and application thereof
Technical Field
The invention belongs to the field of health products, and relates to meal replacement powder for improving intestinal flora and application thereof.
Background
A large number of symbiotic microorganisms are colonised in the intestinal tract of a human body, and the symbiotic microorganisms form a second organ of the human body, so that the symbiotic microorganisms not only cooperate with a host to participate in the digestion and absorption of nutrient substances, but also play an important role in the maintenance of the health of the human body. In terms of cell number, the number of all cells of the intestinal microorganism is 10 times that of human cells, and the huge microorganism population mainly consists of the following species: two major classes, the phylum firmicutes and the phylum bacteroides. More and more researches show that the composition and diversity of intestinal microorganisms are closely related to the occurrence of various diseases, such as obesity, diabetes, irritable bowel syndrome, ulcerative enteritis, colon cancer, fatty liver and the like. Due to the influence of environment, diet, medicines and the like, the balance of intestinal microorganisms in the original health state is broken, so that the intestinal function is disturbed, and the occurrence of the diseases is further induced.
In recent years, with the improvement of the daily living standard of people, the dietary structure is gradually unbalanced, and the incidence rate of metabolic diseases such as obesity and diabetes is rapidly increased. According to world health organization statistics, about 4.22 hundred million people worldwide have diabetes mellitus in 2014, and 2012, the number of deaths caused by diabetes mellitus reaches 150 ten thousand people. Diabetes is thus the next major public health problem. Diabetes is a disease of hyperglycemic abnormality caused by various factors, mainly due to metabolic disorder caused by insufficient insulin secretion or insulin function deficiency, and common high risk factors causing diabetes are genetic factors, environmental factors and bad lifestyle. Diabetes is accompanied by many complications, such as complicated coronary heart disease, hypertension, myocardial infarction, cerebral apoplexy, senile dementia, parkinson's disease, nephropathy, retinopathy, etc., which seriously reduce the quality of life of patients. Of these, type II diabetes is a type of non-insulin dependent diabetes mellitus, and the number of patients suffering from the type II diabetes mellitus accounts for 90% of the number of patients suffering from all diabetes mellitus. Numerous studies have shown that the onset of type two diabetes is closely linked to disorders of the intestinal flora, which in turn is closely linked to the regulation of energy balance and inflammatory response in the host, and that the onset of type two diabetes is mainly caused by insulin resistance and low levels of inflammatory response.
The current hypoglycemic drugs for treating diabetes mellitus comprise sulfonylurea, alpha-glucosidase inhibitors and biguanides, wherein the sulfonylurea mainly promotes insulin secretion, but causes serious liver and kidney injury, and is not suitable for taking in allergic constitution; the alpha-glucosidase inhibitor can inhibit the activities of alpha-amylase and alpha-glucosidase in the intestines and inhibit the hydrolysis of carbohydrate, so that the aim of reducing postprandial blood sugar is fulfilled, but adverse reactions such as abdominal distension, diarrhea and the like are easily caused; biguanides can achieve the purpose of lowering blood glucose by regulating blood glucose transport, such as delaying sugar absorption, promoting glucose decomposition, inhibiting hepatic glucose production, and increasing the amount of glucose transfer proteins. The biguanide drugs also have side effects, are easy to cause gastrointestinal discomfort, diarrhea, vomiting and rash, and are easy to lose activity after long-term administration.
Disclosure of Invention
The invention aims to provide meal replacement powder for improving intestinal flora and application thereof.
The dietary composition provided by the invention comprises at least one selected from the group consisting of kudzuvine root powder, coix seed powder, lily powder, inulin and balsam pear powder.
The dietary composition can also comprise radix Puerariae powder, coicis semen powder, bulbus Lilii powder, inulin and fructus Momordicae Charantiae powder.
In the dietary composition, the weight parts of the components are as follows:
1-40 parts of kudzuvine root powder, 10-60 parts of coix seed powder, 2-40 parts of lily powder, 10-50 parts of inulin and 2-40 parts of balsam pear powder.
Xylitol and oat flour may also be included in the dietary composition.
The dietary composition may also consist of xylitol, oat flour, radix Puerariae powder, coicis semen powder, bulbus Lilii powder, inulin and fructus Momordicae Charantiae powder.
In the dietary composition, the weight parts of the components are as follows:
2-40 parts of xylitol, 2-50 parts of oat flour, 1-40 parts of radix puerariae powder, 10-60 parts of coix seed powder, 2-40 parts of lily powder, 10-50 parts of inulin and 2-40 parts of balsam pear powder.
The mesh numbers of the oat flour, the kudzuvine root powder, the coix seed powder, the lily powder, the inulin and the balsam pear powder are all 50-200 meshes, specifically 80 meshes.
The dietary composition is any one of the following compositions a to c:
the composition a comprises the following components in parts by weight:
10-20 parts of xylitol, 12-50 parts of oat flour, 6-30 parts of radix puerariae powder, 28-33 parts of coix seed powder, 10-20 parts of lily powder, 24 parts of inulin and 10-20 parts of balsam pear powder;
the composition b comprises the following components in parts by weight:
10-25 parts of xylitol, 12-42 parts of oat flour, 6-24 parts of radix puerariae powder, 28-38 parts of coix seed powder, 10-25 parts of lily powder, 24 parts of inulin and 10-25 parts of balsam pear powder;
the composition c comprises the following components in parts by weight:
20-25 parts of xylitol, 42-50 parts of oat flour, 24-30 parts of radix puerariae powder, 33-38 parts of coix seed powder, 20-25 parts of lily powder, 24 parts of inulin and 20-25 parts of balsam pear powder.
Specifically, the dietary composition is any one of the following compositions d to f:
the composition d comprises the following components in parts by weight:
10 parts of xylitol, 12 parts of oat flour, 6 parts of kudzuvine root powder, 28 parts of coix seed powder, 10 parts of lily powder, 24 parts of inulin and 10 parts of balsam pear powder;
the composition e comprises the following components in parts by weight:
20 parts of xylitol, 50 parts of oat flour, 30 parts of kudzuvine root powder, 33 parts of coix seed powder, 20 parts of lily powder, 24 parts of inulin and 20 parts of balsam pear powder;
the composition f comprises the following components in parts by weight:
25 parts of xylitol, 42 parts of oat flour, 24 parts of kudzuvine root powder, 38 parts of coix seed powder, 25 parts of lily powder, 24 parts of inulin and 25 parts of bitter gourd powder.
In addition, the application of the dietary composition provided by the invention in preparing a product for improving the intestinal flora structure and the application of the dietary composition in preparing a product for preventing and/or treating diabetes also belong to the protection scope of the invention. Wherein the product can be meal replacement powder or dairy product. The improvement of the intestinal flora structure can be specifically realized by increasing the content of the bacteria beneficial to blood sugar and blood lipid regulation, increasing the abundance of the core flora and reducing the content of pathogenic bacteria. Wherein the bacteria beneficial to blood glucose and blood lipid regulation can be lactobacillus (Latobacillus), bacteroides (Bactoides) and Laurus (Blauthia);
the core flora is specifically an allobaculom flora and an Oscillospira flora, wherein the two flora are flora which is dominant in early life, and Oscillospira is related to the reduction of obesity;
the pathogenic bacteria can be at least one of Mucispirillum, odoribacter, pseudomonas and Streptococcus; mucispirilum inhibits colonic mucosa, destroying intestinal barrier; odoribacter is more distributed in large intestine cancer; pseudomonas is an endogenous inflammatory flora.
The dietary composition provided by the invention contains various medicinal and edible homologous traditional Chinese medicinal materials such as kudzuvine root, coix seed, lily, inulin, balsam pear and the like, and is rich in flavone and polysaccharide components. The composition can significantly improve fasting blood glucose and postprandial blood glucose of people with impaired insulin. And can increase the content of probiotics of lactobacillus (Latobacilli), bacteroides (Bactoides) and Laurus (Blauthia) which are beneficial to regulating blood sugar and blood lipid, increase the abundance of core flora (Allobacuum and Oscilospira), and reduce the content of pathogenic bacteria such as Mucispirilum and Odoribacter, pseudomonas, streptococcus. The invention combines the food materials and the prebiotics which can reduce blood sugar, combines the efficacy of the food materials and the efficacy of intestinal microorganisms, plays the role of regulating the balance of organism sugar metabolism together, can effectively reduce blood sugar, avoids the side effects of low blood sugar, too fast fluctuation of blood sugar and the like caused by common blood sugar regulating medicines, can comprehensively promote the health of human bodies by regulating the balance of intestinal flora, and is suitable for long-term use.
The invention has the beneficial effects that: the invention provides an application of a dietary composition in preparing food for regulating intestinal probiotics and harmful bacteria. The inventor observes the influence of the composition on the lipid metabolism of mice through a high-fat feed-induced mouse obesity type II diabetes model by using a high-fat feed, and surprisingly discovers that the dietary composition can regulate the intestinal flora disturbance caused by diet, can obviously change the composition of the intestinal flora, lead the intestinal flora unbalanced in vivo to be normal, further regulate the blood fat and blood sugar indexes of obesity caused by the intestinal flora disturbance caused by diet, can obviously reduce the content of total cholesterol in serum, and can reduce the content of cholesterol and low-density lipoprotein. Through research of metagenomics, the composition is found to be capable of increasing the abundance of probiotics in the intestinal flora of healthy people and reducing the abundance of harmful bacteria in obese and insulin resistant patients.
According to the embodiment of the invention, the composition and the components in the composition, the action and effect of the action composition for regulating intestinal microorganisms and regulating blood sugar are better than those of single components.
The components of the composition in the invention are all derived from food with homology of medicine and food and are derived from nature. And the medicine does not contain chemical agents, has no toxic or side effect, and is safe and reliable. The material sources are wide and can be easily obtained, the components are scientifically combined, the curative effect is obvious, and the synergistic growth effect is achieved. The manufacturing process is simple, the storage and application are safe, and the product is easy to accept by consumers.
The invention realizes the effects of safely, remarkably reducing blood sugar and controlling diet through scientific compatibility of purely natural edible raw materials. Provides a new choice for people to regulate blood sugar.
The product can achieve the effect of reducing blood sugar by adjusting intestinal microorganisms of the people with T2D diabetes mellitus, and the raw materials are common food materials without toxic or side effects, so that daily needs of people are met, and the purpose of health can be achieved. New studies have shown that many diseases, sub-health conditions are caused by disorders of the intestinal microbiota. The balance of the intestinal bacterial flora is of great importance for physical health, while some bad habits in life disturb the "peace world" of the intestinal tract: 1. long-term unbalanced diet. Such as excessive intake of meat or vegetables, long-term eating of unhealthy foods, etc. 2. Food contaminated with bacteria is ingested. Reducing resistance, and "deteriorating" the conditional pathogenic bacteria, or taking harmful bacteria too much, unbalanced intestinal flora, and diarrhea symptoms. 3. And the age increases. With age, part of beneficial bacteria are reduced, harmful bacteria are increased, and body immunity is weakened. 4. Certain drugs are used. Excessive administration of antibiotics causes unbalanced intestinal flora and reduced immunity. 5. Gastrointestinal dysfunction. The organic cause causes the intestinal flora to be unbalanced and the immunity to be reduced. 6. Constipation, etc. The too long residence time of the feces in the intestinal tract can restrict the growth of certain bacteria, and cause the imbalance of the living environment of the flora. Type II diabetes is a metabolic disease itself, which can be controlled by regulating diet during insulin impairment and early stage of diabetes. The product achieves the purpose of controlling blood sugar by not taking common medicines, but achieving the purposes of regulating the disordered intestinal flora of the T2D diabetes patient, enriching the probiotics amount of the T2D diabetes patient and regulating the blood sugar by the combined action of the composition, thereby having very broad prospect.
Drawings
FIG. 1 is the effect of example 1 (composition 1) on the structure of intestinal flora in hyperglycemic mice.
FIG. 2 is the effect of example 2 (composition 2) on the structure of intestinal flora in hyperglycemic mice.
FIG. 3 is the effect of example 3 (composition 3) on the structure of intestinal flora in hyperglycemic mice.
Figure 4 shows the effect of meal replacement powder of composition 3 on the structure of intestinal flora in hyperglycemic people.
Detailed Description
The invention will be further illustrated with reference to the following specific examples, but the invention is not limited to the following examples. The methods are conventional methods unless otherwise specified. The starting materials are available from published commercial sources unless otherwise specified. In the examples described below, inulin was used from Sansheng Kogyo Biotechnology Co., ltd; the coix seed used was purchased from Guangdong party pharmaceutical Co.
Example 1
Composition 1: weighing 10 parts by weight of xylitol, 12 parts by weight of oat, 6 parts by weight of radix puerariae, 28 parts by weight of coix seed, 10 parts by weight of lily, 24 parts by weight of inulin and 10 parts by weight of balsam pear powder, respectively crushing, sieving with a 80-mesh sieve, and uniformly mixing to obtain the dietary composition provided by the invention.
Example 2
Composition 2: weighing 20 parts by weight of xylitol, 50 parts by weight of oat, 30 parts by weight of radix puerariae, 33 parts by weight of coix seed, 20 parts by weight of lily, 24 parts by weight of inulin and 20 parts by weight of balsam pear powder, respectively crushing, sieving with a 80-mesh sieve, and uniformly mixing to obtain the dietary composition provided by the invention.
Example 3
Composition 3: 25 parts of xylitol, 42 parts of oat, 24 parts of kudzuvine root, 38 parts of coix seed, 25 parts of lily, 24 parts of inulin and 25 parts of balsam pear powder are weighed, respectively crushed and sieved by a 80-mesh sieve, and uniformly mixed to obtain the dietary composition provided by the invention.
Example 4 animal experiments to lower blood glucose
The composition prepared in example 1 was evaluated according to the evaluation method of the animal experiment for the auxiliary blood glucose reducing function of the ministry of health "technical Specification for inspection and evaluation of health food" (2003), and the specific procedures are as follows:
1 test method
In the embodiment, the treatment effect of 3 meal replacement powder combinations in the embodiments 1, 2 and 3 on the type 2 diabetes (T2D) is examined by taking meal replacement powder for 2 months in a model mouse which is induced to cause insulin resistance and early type 2 diabetes (T2D) by feeding high-fat feed.
1. Modeling of T2D mice: the test mice are C57bL/6 mice, 8 mice in 8 weeks of age, 8 mice in each group are subjected to SPF (specific pathogen free) level in the environment of mice test, and are subjected to grouping molding after being subjected to adaptive feeding for 1 week. The modeling method adopts a high-fat induction method, and the obvious difference between the fasting blood glucose value and the insulin resistance experiment and the comparison group mice can be used as insulin-impaired and diabetes early model mice.
2. Experimental grouping:
(1) Model (model) group: the T2D model mice are subjected to gastric lavage by using normal saline;
(2) Composition 1: mice in the T2D model were treated with composition 1 of example 1 instead of 10% high fat diet;
(3) Composition 2: mice in the T2D model were treated with composition 2 of example 2 instead of 10% high fat diet.
(4) Composition 3: mice in the T2D model were treated with composition 3 of example 3 instead of 10% high fat diet.
3 test procedure
Experiment preparation:
the addition amount of the compositions 1, 2 and 3 in the mouse feed was determined, and meal replacement powder and high-fat diet were synthesized into the mouse diet at the mouse feed company.
The experimental process comprises the following steps:
experiments were performed according to the grouping, and treatment was started after T2D molding for 2 months. The feeding activity of the mice was recorded daily and the body weight was weighed, tail vein blood collection was performed every 2 weeks, fasting blood glucose levels of the mice were measured, and glucose tolerance (OGTT) of the mice was measured at the fourth week of treatment and at the end of the experiment. Mice were sacrificed 2 months after the test, all mice were harvested from the eyeballs, de-necked, and tested for Total Cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) in the serum.
4 test results
Weight change
As shown in Table 1, the weight of mice in the high fat diet-induced model group, composition 1 group, composition 2 group, and composition 3 group increased after the high fat diet induction for 8 weeks. After 8 weeks, mice were subjected to interventional therapy. After 8 weeks of treatment, the weight of each of the compositions 1, 2, and 3 was reduced compared to the model group.
TABLE 1 weight variation in mice
Packet numbering 0 week Molding for 4 weeks Molding for 8 weeks Intervention for 4 weeks Intervention for 8 weeks
Model group (g) 22.48 27.99 32.42 36.87 40.24
Composition 1 group (g) 21.56 27.76 32.59 34.12 36.76
Composition 2 group (g) 21.54 28.42 33.23 35.25 38.45
Composition 3 group (g) 21.67 28.23 32.76 32.35 32.79
Fasting blood glucose and OGTT results
As shown in tables 2 and 3, after the induction of the high fat diet for 8 weeks, the mice in the composition 1 group, the composition 2 group and the composition 3 group induced by the high fat diet have obvious difference (P < 0.05) between the area under OGTT curve (AUC) and the model group measured by the OGTT insulin resistance test. After 8 weeks of meal replacement powder dry pretreatment, the composition has a reduced fasting blood glucose compared with the model group, and the reduction is obvious (P < 0.05). The OGTT test showed a significant decrease in area under the OGTT curve (AUC) with significant differences (P < 0.05) compared to the model group, with the differences being most pronounced in group 3.
TABLE 2 fasting blood glucose changes in mice
Figure BDA0001527833000000061
Figure BDA0001527833000000071
TABLE 3 results of OGTT test in mice
Figure BDA0001527833000000072
Blood fat detection result
After the end of the experiment, the blood lipid of the mice was detected by serum, including Total Cholesterol (TC), triglyceride (TG), low Density Lipoprotein (LDLC) and High Density Lipoprotein (HDLC), and the detection results are shown in table 4, and compared with the model group, the total hepatic sterol TC and the low density lipoprotein LDLC of the composition 1 group were significantly reduced, and the difference was significant (P < 0.05). The triglyceride is reduced, and the difference is not obvious. The high density lipoprotein has a certain rise in the composition 1 group, and the difference is not obvious. In composition 3, the triglyceride, total cholesterol and low density lipoprotein were all significantly reduced, and the high density lipoprotein was not significantly different.
TABLE 4 blood lipid detection results in mouse serum
Packet numbering TC(mmol/L) TG(mmol/L) LDLC(mmol/L) HDLC(mmol/L)
Model group 6.82 1.74 2.45 2.76
Composition 1 group 5.38* 1.03 1.65* 3.16
Composition 2 group 6.24 1.69 2.47 2.48
Composition 3 group 3.56* 0.68* 1.04* 4.58
Intestinal microorganism detection results
TABLE 5 data of composition 1 effect on intestinal microorganisms in hyperglycemic mice (unit: relative abundance%)
Figure BDA0001527833000000073
Figure BDA0001527833000000081
Table 6, data on the effect of composition 2 on intestinal microorganisms in hyperglycemic mice (unit: relative abundance%)
Model group Composition 2 group
Lactobacillus 2.53 14.08
Allobaculum 19.53 18.15
Oscillospira 17.73 13.62
Mucispirillum 6.07 4.08
Blautia 2.20 4.08
Bacteroides 2.27 0.85
Table 7, data on the effect of composition 3 on intestinal microorganisms in hyperglycemic mice (unit: relative abundance%)
Model group Composition 3 group
Allobaculum 7.55 8.85
Oscillospira 4.85 14.56
Lactobacillus 1.00 1.33
Bacteroides 1.14 2.44
Rikennella 0.87 2.89
Pseudomonas 3.00 1.11
Odoribacter 2.29 0.00
FIGS. 1 to 3 show the results of the regulation of intestinal flora structures of the hyperglycemic mouse model by the compositions 1, 2, and 3 obtained in examples 1, 2, and 3, respectively.
As can be seen from the figure, the composition can significantly increase the abundance of probiotics (lactobacillus (bacteriodes), lautella (Blautia), etc.), inhibit harmful bacteria (mucispirilum, odorib, pseudobacteria, streptococcus, etc.), and increase or maintain the content of healthy population dominant bacteria allobacilum and Oscillospira.
Example 5, crowd experiment verifies results
1 test method
80 insulin impaired or early-discovered type II diabetics were selected on a voluntary basis, 50 men, 30 women, and between 45 and 55 years of age. Has no complications of liver and kidney, adopts the contrast design before, during and after trial feeding
Volunteers were divided into 2 groups, and the normal diet of diabetic patients before breakfast and lunch was performed in the experimental group, and high-fat and high-sugar foods were contraindicated. The dinner was served by 50g of meal replacement powder of the composition 3 in example 3, and the meal replacement powder was eaten after being soaked in boiled water. The control group did not eat meal replacement powder for dinner according to the previous eating habit. The administration is continued for 30 days. The patient was monitored for changes in blood pressure, stool and urine, body weight, and blood glucose (by glucose oxidase) was measured on an empty stomach and 2 hours after meal.
2 test criterion
The effect is shown: the basal symptoms disappear, and the blood sugar is reduced by not more than 30.0% after 2 hours after fasting or postprandial treatment.
The method is effective: the basic symptoms are obviously improved, and the blood sugar is reduced by not more than 10.0% after fasting and 2 hours after meal compared with the blood sugar before treatment.
Invalidation: the basic symptoms are not obviously improved, and the blood sugar is reduced by less than 10.0 percent after fasting and 2 hours after meal compared with the blood sugar before treatment.
3 test results
Blood sugar detection result of people who try to eat
Table 8, blood sugar test results of the population
Figure BDA0001527833000000091
As can be seen from table 8, after the population experiment is finished, the fasting blood glucose of the experimental group is obviously reduced, the effect is obvious, and the reduction rate reaches 29.3%. The postprandial blood glucose reduction rate reaches 23.17 percent. There was no significant change before and after the control test. Therefore, the meal replacement powder has obvious blood sugar reducing and health care functions by improving the intestinal flora structure, and has no harm to the health of the tested population, namely the meal replacement powder composition has obvious blood sugar reducing function.
The results of intestinal microorganism detection in crowd experiments are shown in fig. 4 and table 9, and the results show that the meal replacement powder can be taken, so that the content of probiotic lactobacillus (Latobacilus) can be obviously improved, and the harmful bacteria Mucispirilum can be reduced. And increasing or maintaining the content of dominant bacteria allobaculom and oscellospira in healthy population.
Table 9, data on the effect of meal replacement powder of composition 3 on intestinal microorganisms in hyperglycemic people
Figure BDA0001527833000000092
Figure BDA0001527833000000101

Claims (5)

1. A dietary composition characterized by: the dietary composition consists of xylitol, oat flour, kudzuvine root powder, coix seed powder, lily powder, inulin and balsam pear powder;
wherein 25 parts of xylitol, 42 parts of oat flour, 24 parts of radix puerariae powder, 38 parts of coix seed powder, 25 parts of lily powder, 24 parts of inulin and 25 parts of balsam pear powder.
2. The dietary composition of claim 1, wherein: the mesh numbers of oat flour, kudzuvine root powder, coix seed powder, lily powder, inulin and balsam pear powder are all 50-200 meshes.
3. The dietary composition of claim 2, wherein: the meshes of oat flour, kudzuvine root powder, coix seed powder, lily powder, inulin and balsam pear powder are all 80 meshes.
4. Use of a dietary composition according to any one of claims 1 to 3 for the preparation of a product for improving the structure of the intestinal flora.
5. Use of a dietary composition according to any of claims 1-3 for the preparation of a product for assisting in lowering blood glucose.
CN201711447314.6A 2017-12-27 2017-12-27 Meal replacement powder for improving intestinal flora and application thereof Active CN109965290B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711447314.6A CN109965290B (en) 2017-12-27 2017-12-27 Meal replacement powder for improving intestinal flora and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711447314.6A CN109965290B (en) 2017-12-27 2017-12-27 Meal replacement powder for improving intestinal flora and application thereof

Publications (2)

Publication Number Publication Date
CN109965290A CN109965290A (en) 2019-07-05
CN109965290B true CN109965290B (en) 2023-06-20

Family

ID=67071164

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711447314.6A Active CN109965290B (en) 2017-12-27 2017-12-27 Meal replacement powder for improving intestinal flora and application thereof

Country Status (1)

Country Link
CN (1) CN109965290B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111213877A (en) * 2020-01-21 2020-06-02 天津天福康生物科技有限公司 Meal replacement powder with function of regulating organism metabolism and preparation method thereof
CN112841533A (en) * 2021-02-01 2021-05-28 四川斯力健农业科技有限公司 Weight-losing meal replacement composition and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1545943A (en) * 2003-11-28 2004-11-17 南宁领标生物技术有限责任公司 Processing technique for compound product of kudzu root and bitter gourd
CN102697060A (en) * 2012-05-23 2012-10-03 广东省农业科学院农业生物技术研究所 Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof
CN103830496A (en) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 Blood glucose reduction resistant composition
CN104585746A (en) * 2014-12-23 2015-05-06 山东世纪春食品有限公司 Production method of special dietary food for diabetes patients for eating

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1545943A (en) * 2003-11-28 2004-11-17 南宁领标生物技术有限责任公司 Processing technique for compound product of kudzu root and bitter gourd
CN102697060A (en) * 2012-05-23 2012-10-03 广东省农业科学院农业生物技术研究所 Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof
CN103830496A (en) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 Blood glucose reduction resistant composition
CN104585746A (en) * 2014-12-23 2015-05-06 山东世纪春食品有限公司 Production method of special dietary food for diabetes patients for eating

Also Published As

Publication number Publication date
CN109965290A (en) 2019-07-05

Similar Documents

Publication Publication Date Title
CN106619743A (en) Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink
CN107496850B (en) It is a kind of adjust enteral microecological formulation formula and application
CN106174585A (en) Hypoglycemic compositions and hypoglycemic compound probiotic spy&#39;s dietary seafood
CN110150669B (en) Probiotic composition suitable for diabetic patients and application thereof
CN104413334A (en) Edible composition as well as preparation method and application thereof
CN111972670A (en) Composition for relaxing bowel, solid beverage and application
CN106176833A (en) A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof
CN109125525B (en) Composition for preventing and treating cardiovascular diseases and preparation method and application thereof
CN110623182A (en) Probiotic plant solid beverage for treating hyperuricemia and gout
EP2223697A1 (en) Lactic acid bacterium-containing preparation
CN108283285A (en) A kind of health-care physiotherapeutic food of diabetes
CN106690331A (en) Kelp dietary fiber granules and preparation method thereof
CN106729092A (en) A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application
CN111557404A (en) Digestion-aiding probiotic solid beverage and preparation method thereof
CN112586744A (en) Probiotic tablet capable of controlling body weight and preparation method thereof
JP2009084215A (en) Inflammatory bowel disease prophylactic or therapeutic agent
CN109965290B (en) Meal replacement powder for improving intestinal flora and application thereof
CN105707378A (en) Black-highland barley coffee with effect of slimming
CN105613882A (en) Black barley hypoglycemic tea (milky tea)
CN114452308A (en) Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent
CN108653298B (en) Monosaccharide composition, pharmaceutical preparation and application thereof
CN108523123A (en) A kind of full nutritional support food of diabetes
TWI744028B (en) Prebiotic composition for promoting growth of clostridium butyricum and uses thereof
CN109043555A (en) A kind of Special food and preparation method thereof that hyperglycemic patients are edible
CN110279720B (en) Processed maggot product and application thereof in regulating intestinal flora

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant